Lulizumab pegol
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | glycoprotein CD28 |
| Identifiers | |
| CAS Number | 1421830-13-8 |
| ATC code | none |
| IUPHAR/BPS | 8460 |
| Chemical data | |
| Formula | C552H859N149O164S4 |
| Molecular mass | 52 kg/mol |
Lulizumab pegol[1] is a monoclonal antibody designed for the treatment of autoimmune diseases.[2]
This drug was developed by Bristol-Myers Squibb.
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Lulizumab Pegol, American Medical Association.
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Monoclonal antibody stubs
- Monoclonal antibodies
